Sweis, Randy F.

WNT/β-catenin pathway activation correlates with immune exclusion across human cancers

Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersWnt/β-catenin signaling in development and cancer

Cited by 722

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

Meric-Bernstam, F., Sweis, R. F., Hodi, F. S., Messersmith, W. A., Andtbacka, R. H. I., Ingham, M., Lewis, N., Chen, X., Pelletier, M., Chen, X., et al. (2022) · Clinical Cancer Research

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 418

Melanoma and microbiota: Current understanding and future directions

Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 89

Mechanistic and pharmacologic insights on immune checkpoint inhibitors

Sweis, R. F., & Luke, J. J. (2017) · Pharmacological Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 37